U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264647) titled 'Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)' on Nov. 24.
Brief Summary: A Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC.
Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR, ALK, ROS1, RET).
Study Start Date: March 27
Study Type: INTERVENTIONAL
Condition:
Stage III NSCLC
Intervention:
DRUG: Tislelizumab
Compared to clinical practice in Italy this trial is adding a neoadjuvant chemoimmuno treatment with adjuvant immuno
PROCEDURE: surgery (any volume) an...